Clinical development of histone deacetylase inhibitor romidepsin.
Histone deactylase inhibitors have emerged as a promising epigenetic therapy for neoplasic indications. The US Food and Drug Administration granted approval to romidepsin for treatment of cutaneous T cell lymphoma (CTCL) in 2009. Phase I/II trials of romidepsin as monotherapy or hybird therapy have demonstrated substantial efficacy profoundly in CTCL and peripheral T-cell lymphoma and marginally in other hematogological malignancies and solid tumors, with a tolerable safety and toxicity profile. The current status of the clinical evaluation of romidepsin is detailed in the present contribution.